Today: 9 June 2026
Planet Labs stock rises on Clear Street $22 target hike as insider sale notices surface
30 December 2025
1 min read

Planet Labs stock rises on Clear Street $22 target hike as insider sale notices surface

NEW YORK, December 30, 2025, 02:00 ET — Market closed.

  • Planet Labs shares closed up 2.7% at $19.87 on Monday.
  • Clear Street raised its price target to $22 from $16 and reiterated a Buy rating.
  • SEC filings showed CEO Will Marshall and another insider filed notices to sell shares.

Planet Labs PBC shares rose 2.7% to $19.87 at Monday’s close after Clear Street raised its price target on the satellite-imagery company to $22 from $16 and maintained a Buy rating. The brokerage pointed to growth potential as Planet pairs its imagery with AI-driven analytics and said it sees a path to the “Rule of 40” benchmark — where revenue growth plus EBITDA margin equals 40 — by fiscal 2028. The stock traded between $18.75 and $20.13 and is near a 52-week high of $20.99. Investing.com Canada

The call matters heading into the final trading days of the year, when liquidity often thins and momentum names can swing sharply on incremental research and positioning shifts.

It also lands alongside fresh insider selling disclosures, which can draw extra scrutiny when a stock is trading near multi-month highs.

A Form 144 filing dated Monday showed CEO and co-founder Will Marshall filed a notice to sell 200,000 shares, with an aggregate market value listed at about $4.06 million and an approximate sale date of Dec. 26. A separate Form 144 filing showed Robert H. Schingler Jr. filed to sell 73,782 shares, with an aggregate market value listed at about $1.50 million, also with an approximate sale date of Dec. 26.

Form 144 is a notice filed with the U.S. Securities and Exchange Commission when an insider intends to sell certain securities, often tied to restricted stock or shares held by control persons. The filings also referenced prior sales under Rule 10b5-1 plans, which are pre-arranged trading programs meant to reduce the appearance of trading on non-public information.

Planet’s latest earnings update earlier this month helped set the backdrop for the stock’s year-end run. The company reported third-quarter fiscal 2026 revenue of $81.3 million, up 33% from a year earlier, and guided for fourth-quarter revenue of about $76 million to $80 million and full-year fiscal 2026 revenue of about $297 million to $301 million. “We delivered a strong third quarter, marked by continued momentum in the business,” Marshall said in the results release. SEC

That guidance leaves investors focused on whether Planet can sustain growth while keeping a lid on costs, especially as it invests in new satellites and analytics offerings and tries to convert contract wins into recurring revenue.

Before the next session opens, traders will be watching whether the stock can hold the $20 area after Monday’s run-up, or whether profit-taking and insider-sale headlines draw sellers into year-end.

Investors will also track any follow-on disclosures around insider activity and whether additional analyst notes land ahead of the open, which can matter more when volumes are lighter than usual.

Looking beyond the next session, earnings calendars such as Zacks list Planet’s next report as expected around March 19, 2026, keeping the focus on delivery against management’s latest quarterly and full-year targets.

Stock Market Today

  • Invest in India’s Top 500 Companies with 3 Low-Cost Index Funds
    June 9, 2026, 10:10 AM EDT. Investors can access India's top 500 companies efficiently through three non-overlapping index funds: Nifty 100 (large-cap), Nifty Midcap 150, and Nifty Smallcap 250. The Nifty 100 Index Fund includes India's top 100 large-cap companies by market capitalization, spanning 17 sectors, and offers resilience in downturns. Common holdings such as HDFC Bank, Reliance Industries, and Infosys provide exposure to key economic sectors. Using these three funds prevents portfolio overlap, ensuring true diversification across market segments. Choices for Nifty 100 Index Funds include Axis, HDFC, and Bandhan, with options for systematic investment plans (SIPs). This strategy offers low cost, broad exposure, and balanced risk for investors seeking diversified growth in Indian equities.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Next Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Go toTop